シミュレイション内科　心不全を探る

出版社： 永井書店
著者：
発行日： 2005-06-10
分野： 臨床医学：内科  >  心臓
ISBN： 4815917213
電子書籍版： 2005-06-10 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,350 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,675 円(税込)

購入する

商品紹介

本書は、研修医やレジデントの方に心不全の臨床をトレーニングしていただくのに最適の材料である。疾患編では、30の病態を取り挙げているので、臨床でよく遭遇するケースはほとんど網羅している内容となっている。

目次

  • シミュレイション内科　心不全を探る

    ―目次―

    総論
    　1．心不全の病態
    　2．拡張機能障害
    　3．急性心不全の病態と治療
    　4．心筋症
    　5．心筋炎の診断と治療
    　6．慢性心不全の薬物療法とEBM
    　7．心不全の非薬物治療
    　8．心臓移植の現状
    　9．心不全と再生療法

    疾患編
    　1．急性心筋梗塞と診断、血行再建術はうまくいったが、
    　　　血圧低下が続いている！？
    　2．突然の胸痛に続いて　全身倦怠感・失神が生じた！？
    　3．心筋梗塞で入院中　回復していたが急に呼吸が苦しくなった！？
    　4．年末宴会で飲酒時　冷汗と腹部不快感あり
    　　　3月に階段昇降で呼吸困難　動悸！？
    　5．最近脈が乱れる　坂道で息切れが…！？
    　6．労作時に胸が痛い　ふらつきも感じる！？
    　7．背が高く指の長い患者　最近夜寝苦しくなる！？
    　8．以前より風邪をひきやすかった
    　　　最近足がむくんで、急いで歩くと息切れが！？
    　9．急性心筋梗塞か？　胸痛および心電図異常のため
    　　　緊急冠動脈造影を施行した高齢女性
    　10．出産直後から息切れ　足のむくみが…！？
    　ほか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.10 掲載の参考文献
1) Morgan JP:Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Eng J Med 325:625, 1991.
 
2) Mackrill jj:Protein-protein interactions in intracellular Ca2+-release channel function. Biochem J 337:345-361, 1999.
PubMed
3) Schlotthauer K, Achattmann J, Bers DM, et al:Frequency-dependent changes in contribution of SR Ca2+to Ca2+transients in failing hurnan myocardium asessed with ryanodine. J Mol Cell Cardiol 30:1285-1294, 1998.
 
4) Bing OHL, Brooks WW, Conrad CH, et al:Intracellular calcium transient in myocardium from spontaneously hypertensive rats during the transition to heart failure. Circ Res 68:1390, 1991.
 
5) Gwathmey PJ, Warren SE, Briggs GM, et al:Diastolic dysfunction in hypertrophic cardiomyopathy:effect on active force generation during systole. J Clin Invest 87:1023, 1991.
 
6) Beuckelmann DJ, Nabauer M, Erdmann E:Intracellular calcium handling in isolated ventricular myocytes from pattients with terminal heart failure. Circulation 85:1046-1055, 1992.
 
7) Marx SO, Reiken S, Hisamatsu Y, et al:PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor):defective regulation in failing hearts. Cell 101:365-376, 2000.
PubMed
8) Marx SO, Reiken S, Hisamatsu Y, et al:Phosphorylation-dependent Regulation of Ryanodine Receptors:A Novel Role for Leucine/Isoleucine Zippers. Journal of Cell Biology 153:699-708, 2001.
PubMed
9) Yano M, Ono K, Ohkusa T, et al:Altered stoichiometry of FKBP 12.6 versus ryanodine receptor as a cause of abnormal Ca2+ leak through ryanodine receptor in heart failure. Circulation 102:2131-2136, 2000.
 
10) Marks AR:Cardiac intracellular calcium release channels Role in heart failure. Circ Res 87:8-11, 2000.
PubMed
11) Marks AR:Ryanodine receptors/calcium release channels in heart failure and sudden cardiac death. J Mol Cell Cardiol 33:615-624, 2001.
PubMed
12) 蔦本尚慶, 前田圭子, 和田厚幸ほか:慢性心不全における代償破綻と悪化サイクル, 入退院を繰り返す慢性心不全の臨床 (和泉徹, 麻野井英次, 小玉誠, 編), pp30-38,東京, 医学書院, 2002.
 
13) Cohn JN, Levine TB, Olivari MT, et al:Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 311:819-823, 1984.
PubMed
14) Studer R, et al:Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest 94:301-310, 1994.
PubMed
15) Mukoyama M, Nakao K, Saito Y, et al:Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 323:757-758, 1990.
PubMed
16) Yasue H, Yoshimura M, Sumida H, et al:Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195-203, 1994.
PubMed
17) Tsutamoto T, Kinoshita M:The diagnostic and prognostic value of BNP and proANP in congestive heart failure. Heart Failure 14:145-151, 1998.
 
18) Gottlieb SS, Kukin ML, Ahern D, et al:Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 13:1534-1539, 1989.
PubMed
19) Rouleau JL, Packer M, Moye L, et al:Prognostic value of neurohumoral activation in patients with an acute myocardial infarction:Effect of captopril. J Am Coll Cardiol 24:583-591, 1994.
PubMed
20) Omland T, Aakvaag A, Bonarjee VVS, et al:Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction:Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93:1963-1969, 1996.
 
21) Tsutamoto T, Wada A, Maeda K, et al:Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure:prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96:509-516, 1997.
PubMed
22) Cowie M, Struthers AD, Wood DA, et al:Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350:1349-1353, 1997.
PubMed
23) Tsutamoto T, Hisanaga T, Fukai D, et al:Prognostic value of plasma soluble intercellilar adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 76:803-808, 1995.
PubMed
24) Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 23:1427-1433, 1994.
PubMed
25) Tsutamoto T, Wada A, Hisanaga T, et al:Relation between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. J Am Coll Cardiol 33:530-537, 1999.
 
26) Krum H, Gu A, Wilshire-Clement M, et al:Importance of endothelin in exercise intolerance of heart failure. Am J Cardiol 75:1282-1283, 1995.
 
27) Jougasaki M, Rodeheffer RJ, Redfield MM, et al:Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 97:2370-2376, 1996.
PubMed
28) 篠山重威:心不全発症の機序. 日本内科学会誌 87:1667-1681, 1998.
 
P.15 掲載の参考文献
1) Senni M, Tribouilloy CM, Rodeheffer RJ, et al:Congestive heart failure in the community:a study of all incident cases in Olmsted County, Minnesota, 1991. Circulation 98:2282-2289, 1998.
PubMed
2) Tsutsui H, Tsuchihashi M, Takeshita A:Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88:530-533, 2001.
PubMed
3) Gandhi SK, Powers JC, Nomeir AM, et al:The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344:17-22, 2001.
PubMed
4) Zile MR, Baicu CF, Gaasch WH:Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350:1953-1959, 2004.
PubMed
5) Pinamonti B, Zecchin M, diLenarda A, et al:Persistence of restrictive left ventricular filling pattern in dilated cardiomyopathy:an ominous prognostic sign. J Am Coll Cardiol 29:604-612, 1997.
 
6) Gilbert JC, Glantz SA:Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res 64:827-852, 1989.
PubMed
7) Yamamoto K, Redfield MM, Nishimura RA:Analysis of left ventricular diastolic function. Heart 75 (Suppl 2):27-35, 1996.
 
8) Redfield MM, Jacobsen SJ, Burnett JC Jr, et al:Burden of systolic and diastolic ventricular dysfunction in the community:appreciating the scope of the heart failure epidemic. JAMA 289:194-202, 2003.
PubMed
9) Yamaguchi H, Yoshida J, Yamamoto K, et al:Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 43:55-60, 2004.
PubMed
10) Sakata Y, Masuyama T, Yamamoto K, et al:Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats:different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol 37:293-299, 200.
 
11) Yamamoto K, Masuyama T, Sakata Y, et al:Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens 20:753-761, 2002.
 
12) Nishikawa N, Masuyama T, Yamamoto K, et al:Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol 38:1539-1545, 2001.
PubMed
13) Philbin EF, Rocco TA, Jr:Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 134:188-195, 1997.
PubMed
14) Chen HH, Lainchbury JG, Senni M, et al:Diastolic heart failure in the community:clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 8:279-287, 2002.
PubMed
15) Yusuf S, Pfeffer MA, Swedberg K, et al:Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial. Lancet 362:777-781, 2003.
PubMed
16) Dauterman KW, Go AS, Rowell R, et al:Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail 7:221-228, 2001.
 
P.24 掲載の参考文献
1) Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopaties. Br Heart J 44:672-673, 1980.
 
2) Fuster V, Gersh BJ, Giuliani ER, et al:The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 47:525-531, 1981.
PubMed
3) Kodama M, Matumoto Y, Fujiwara M, et al:In vivo lymphocyte mediated myocardial injuries demonstrated by adoptive transfer of experimental autoimmune myocarditis. Circulation 85:1918-1926, 1992.
 
4) Magnusson Y, Wallukat G, Hoebeke J, et al:Autoimmunity in idiopathic dilated cardiomyopathy. Circulation 89:2760-2767, 994.
 
5) Mckenna W, Deanfield J, Faruqui A, et al:Prognosis in hypertrophic cardiomyopathy;role of age and clinical, echocardiographic and hemodynamic feature. Am J Cardiol 47:532-538, 1981.
 
6) Maron MS, Olovotto I, Marson BJ, et al:Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295-303, 2003.
 
7) Hamada M, Shigematsu Y, Ikeda S, et al:Antiarrhythmic drug, cibenzoline:anew approach to medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 96:1520-1524, 1997.
 
8) Lakkis NM, Nagueh SF, Kleiman NS, et al:Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98:1750-1755, 1998.
PubMed
9) Fontaine G, et al:Arrhythmogenic right ventricular dysplasia. In:Zipes DP and Jalife J (Eds):Cardiac Electrophysiology. WB Saunders:754-769, 1995.
 
10) Corrado D, Basso C, Camerini F, et al:Spectrum of clinicopathological manifestations of Arrhythmogenic right ventricular cardiomyopathy/dysplasia:A multicenter study. J Am Coll Cardiol 30:1512-1520, 1997.
PubMed
P.30 掲載の参考文献
1) Japanese circulation society task force committee on chronic myocarditis:Guideline for diagnosing chronic myocarditis. Jpn Circ J 60:263-264, 1996.
PubMed
2) 河村慧四郎, ほか:ウイルス性あるいは特発性心筋炎臨床診断の手引き. 厚生省特定疾患特発性心筋症調査研究班昭和61年度研究報告集. pp 11, 1987.
 
3) 河村慧四郎, 北浦泰, 出口宏章, ほか:病因分科会:ウイルス性あるいは特発性心筋炎にかんする全国アンケート調査. 厚生省特定疾患特発性心筋症調査研究班,昭和60年度研究報告集, pp 1636, 1986.
 
4) 小出尚志, 北浦泰, 浮村聡, ほか:心筋炎と拡張型心筋症患者の生検心筋におけるエンテロウイルスRNAの検索ム第2報. 厚生省特定疾患特発性心筋症調査研究班,平成4年度研究報告集, pp172-178, 1993.
 
5) 岡田了三, 関口守衛, 河村慧四郎, ほか:心筋生検によるウイルス性ないし特発性心筋炎の病理診断基準. 厚生省特定疾患特発性心筋症調査研究班, 昭和63年度研究報告集, pp181-182, 1989.
 
P.34 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン合同研究班:慢性心不全治療ガイドライン.急性心不全治療ガイドライン. Jpn Circ J 64 (Suppl IV):1023-1165, 2000.
 
2) Hunt SA, et al:ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. Circulation 104:2996-3007, 2001.
PubMed
3) Vasan RS, Levy D:The role of hypertension in the pathogenesis of heart failure:a clinical mechanistic overview. Arch Intern Med 156:1789-1796, 1996.
PubMed
4) The SOLVD investigators:Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691, 1992.
PubMed
5) Cohn JN, et al:Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991.
 
6) The Digitalis Investigation Group:The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525-533, 1997.
 
7) ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002.
PubMed
8) Stevo Julius, et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or aml;odipine:the VALUE randomized trial. Lancet 363:2022-2031, 2004.
 
9) Blood Pressure Lowering Treatment Trialists:Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomized trials. Lancet 362:1527-1535, 2003.
PubMed
10) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994.
PubMed
11) Heart Outcomes Prevention Evaluation Study Investigators:Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000.
PubMed
12) Jong P, Yusuf S, Rousseau MF, et al:Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular dysfunction:a follow-up study. Lancet 361:1843-1848, 2003.
PubMed
13) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001.
PubMed
14) Marc A:Pfeffer et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med, 349:1893-1906, 2003.
 
15) The SOLVD investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991.
PubMed
16) Pitt B, Poole-Wilson PA, et al:Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582-1587, 2000.
PubMed
17) Cohn, et al:Arandomized trial on the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001.
 
18) Pfeffer MA, et al:Effects of candesartan on mortality and morbidity in patients with chronic heart failure:the CHARM-Overall programme. Lancet 362:759-766, 2003.
PubMed
19) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999.
PubMed
20) CIBIS II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):arandomised trial. Lancet 353:9-13, 1999.
 
21) Cohn JN, Archibald DG, Ziesche S, et al:Effect of vasodilator therapy on mortality in chronic congestive heart failure:results of a Veterans Administration Cooperative Study. N Engl J Med 314:1547-1552, 1986.
 
22) Prospective Randomized Amlodipine Survival Evaluation Study Group:Effect of amlodipine on morbidity and mortality in severe chronic heart failure, N Engl J Med 335:1107-1114, 1996.
PubMed
23) The CONSENSUS trial study group:Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316:1429-1435, 1987.
 
24) Packer M, et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001.
PubMed
25) Randomized Aldactone Evaluation Study Investigators:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717, 1999.
 
26) Packer M, et al:Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468-1475, 1991.
 
P.40 掲載の参考文献
1) 松田直樹:心不全の再同期療法. 呼吸と循環 51:1229-1240, 2003.
 
2) Abraham WT, Fisher WG, Smith AL, et al:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002.
PubMed
3) Sutton MG, Plappert T, Abraham WT, et al:Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107:1985-1990, 2003.
 
4) Salukhe TS:Cardiac resynchronization may reduce all-cause mortality:meta-analysis of preliminary COMPANION data with CONTAK-CD, nSync ICD, MIRACLE and MUSTIC. Intemational J Cardiol 93:101-103, 2004.
 
5) The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators:Acomparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576-1538, 1997.
 
6) Moss AJ, Hall WJ, Cannon DS, et al:Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335:1933-1940, 1996.
 
7) Buxton AE, Lee KL, Fisher JD, et al:A randomized study of the prevention of sudden cardiac death in patients with coronary artery disease. N Engl J Med 341:1882-1890, 1999.
PubMed
8) Moss AJ, Zareba W, Hall WJ, et al:Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877-883, 2002.
PubMed
9) Bristow MR, Saxon LA, Boehmer J, et al:Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140-2150, 2004.
 
10) Franco-Cereceda A, McCarthy PM, Blackstone EH, et al:Partial left ventriculectomy for dilated cardiomyopathy:is this an alternative to transplantation? J Thorac Cardiovasc Surg 121:879-893, 2001.
PubMed
11) Rose EA, Gelijns AC, Moskowitz AJ, et al:Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345:1435-1443, 2001
PubMed
P.46 掲載の参考文献
1) Matsuda H, Fukushima N, Sawa Y, et al:First brain dead donor heart transplantation under new legislation in Japan. 日本胸部外科学会雑誌 47:499-505, 1999.
 
2) Kawasaki S, Hashikura Y, Ikegami T, et al:First case of cadaveric liver transplantation in Japan. J Hepatobiliary Pancreat Surg 6:387-390, 1999.
PubMed
3) Barnard CN:Ahuman cardiac transplant:an interim report of a successful operation performed at Groote Schuur Hospital, Cape town. S Afr Med J 41:1271-1274, 1967.
 
4) Grieppe RB:Adecade of human heart transplantation. Transplant Proc 11:285-292, 1979.
 
5) Husenpud JD, Bennett LE, Keck BM, et al:The registry of the International Society for Heart and Lung Transplantation:18th Official Report-2001. J Heart Lung Transplant 20:805-815, 2001.
 
P.51 掲載の参考文献
1) Reinecke H, et al:Survival, integration, and differentiation of cardiomyocyte grafts:astudy in normal and injured rat hearts. Circulation 100:193-202, 1999.
 
2) Soonpaa MH, et al:Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science 264:98-101, 1994.
PubMed
3) Leor J, et al:Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium? Circulation:94 (9 Suppl):II3326, 1996.
 
4) Scorsin M, et al:Can cellular transplantation improve function in doxorubicin-induced heart failure? Circulation 98 (19 Suppl):II151-5, discussion II155-6, 1998.
 
5) Li RK, et al:Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 62:654-660, 1996.
PubMed
6) Scorsin M, et al:Does transplantation of cardiomyocytes improve function of infarcted myocardium P Circulation 96 (9 Suppl):II-188-93, 1997.
 
7) Evans MJ, et al:Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154-156, 1981.
PubMed
8) Klug MG, et al:Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J Clin Invest 98:216-224, 1996.
PubMed
9) Taylor DA, et al:Regenerating functional myocardium:improved performance after skeletal myoblast transplantation. Nat Med 4:929-933, 1998.
PubMed
10) Scorsin M, et al:Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg 2000.
PubMed
11) Murry CE, et al:Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. J Clin Invest 98:2209-2217, 1996.
PubMed
12) Menasche P, et al:Myoblast transplantation for heart failure. Lancet 357:279-280, 2001.
PubMed
13) Menasche P:Skeletal muscle satellite cell transplantation. Cardiovasc Res 58:351-357, 2003.
PubMed
14) Menasche P:Cell transplantation in myocardium. Ann Thorac Surg 75 (6 Suppl):S20-8, 2003.
 
15) Menasche P, et al:Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41:1078-1083, 2003.
PubMed
16) Makino S, et al:Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103:697-705, 1999.
PubMed
17) Orlic D, et al:Bone marrow cells regenerate infarcted myocardium. Nature 410:701-705, 2001.
PubMed
18) Murry CE, et al:Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428:664-668, 2004.
 
19) Balsam LB, et al:Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428:668-673, 2004.
PubMed
20) Rangappa S, Fen C, Lee EH, et al:Related Articles, Links Abstract Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 75:775-779, 2003.
 
21) Planat-Benard V, et al:Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells.
 
22) Orlic D, et al:Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98:10344-10349, 2001.
PubMed
23) Ohtsuka, et al:Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 18:851-853, 2004.
PubMed
24) Zou Y, et al:Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation 108:748-753, 2003.
PubMed
25) Anversa P, et al:Myocyte renewal and ventricular remodelling. Nature 415:240-243, 2002.
PubMed
26) Oh H, et al:Cardiac progenitor cells from adult myocardium:homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 100:12313-12318, 2003.
PubMed
27) Matsuura I, et al:Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem 279:11384-11391, 2004.
 

疾患編

P.60 掲載の参考文献
1) Braunwald E, et al:The stunned myocardium:Prolonged, postischemic ventricular dysfunction. Circulation 66:1146, 1982.
PubMed
2) Kusuoka H, Merban E:Cellular mechanisms of myocardial stunning. Ann Rev Pysiol 54:243-256, 1992.
 
3) Grines CL, et al:A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 328:673-679, 1993.
PubMed
4) Williams DO, et al:Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction:observations from the TIMI」Btrial. Circulation 94:2749-2755, 1996.
 
5) Dilsizian V, Bonow RO:Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation 87:1, 1993.
PubMed
6) Brown KA, Heller GV, Landin RS, et al:Early dipyridamole 99mTc sestamibi single photon emission computed tomographic imaging 2 to 4 days after acute myocardial infarction predicts in-hospital and postdischarge cardiac events:comparison with submaximal exercise imaging. Circulation 100:2060-2066, 1999.
PubMed
7) Previtali M, Poli A, Lanzarini L, et al:Dobutamine stress echocardiography for assessment of myocardial viability and ischemia in acute myocardial infarction treated with thrombolysis. Am J Cardiol 72:124G-130G, 1993.
PubMed
8) Lee KS, Marwick TH, Cook SA, et al:Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 90:2687-2694, 1994.
PubMed
9) Tamaki N, et al:Prediction of reversible iachemia after revascularization. Circulation 91:1697, 1995.
 
P.65 掲載の参考文献
1) Adgey AAI, Mulholand HC, Geddes JS, et al:Incidence, significance and management of early bradyarrhythmias complicating acute myocardial infarction. Lancet 2:1097-1101, 1968.
 
2) Rotman M, Wanger GS, Wallae AG:Bradyarrhythmias in acute myocardial infarction. Circulation 45:703-722, 1972.
 
3) Futami C, Tanuma K, Tanuma Y, et al:The arterial blood supply of the conducting system in normal human hearts. Surg Radiol Anat 25:42-49, 2003.
PubMed
4) Watanabe I, Johnson TA, Buchanan J, et al:Effect of graded coronary flow reduction on ionic, electrical, and mechanical indexes of ischemia in the pig. Circulation 76:1127-1134, 1987.
PubMed
5) Ely SW, Berne RM:Protective effects of adenosine in myocardial ischemia. Circulation 85:893-904, 1992.
PubMed
6) Farrell TG, Paul V, Cripps TR, et al:Baroreflex sensitivity and electrophysiological correlates in patients after acute myocardial infarction. Circulation 83:945-952, 1991.
PubMed
7) Harpaz D, Behar S, Gottlieb S, et al:Complete atrioventricular block complicating acute myocardial infarction in the thrombolytic era. SPRINT Study Group and the Israeli Thrombolytic Survey Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Am Coll Cardiol 34:1721-1728, 1999.
 
8) Archbold RA, Sayer JW, Ray S, et al:Frequency and prognostic implications of conduction defects in acute myocardial infarction since the introduction of thrombolytic therapy. Eur Heart J 19:893-898, 1998.
 
9) Goldberg RJ, Zevallos JC, Yarzebski J, et al:Prognosis of acute myocardial infarction complicated by complete heart block (the Worcester Heart Attack Study). Am J Cardiol 69:1135-1141, 1992.
PubMed
10) Tans AC, Lie KI, Durrer D:Clinical setting and prognostic significance of high degree atrioventricular block in acute inferior myocardial infarction. Am Heart J 99:4-8, 1980.
PubMed
11) Nicod P, Gilpin E, Dittrich H, et al:Long-term outcome in patients with inferior myocardial infarction and complete atrioventricular block. J Am Coll Cardiol 12:589-594, 1988.
PubMed
12) Feigl D, Aschenazy J, Kishon Y, et al:Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol 4:35-38, 1984.
PubMed
13) Kyriakidis M, Barbetseas J, Antonopoulos A, et al:Early atrial arrhythmias in acute myocardial infarction. Chest 101:944-947, 1992.
PubMed
14) Strasberg B, Bassevich R, Mager A, et al:Effects of aminophylline on atrioventricular conduction in patients with late atrioventricular block during inferior wall acute myocardial infarction. Am J Cardiol 67:527-528, 1991.
PubMed
P.70 掲載の参考文献
1) Ellen C Keeley, Judith A Boura, Cindy L Grines:Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction:a quantitative review of 23 randomised trials. Lancet 361:13-20, 2004.
 
2) Elliott Antman, Jean-Pierre Bassand, Werner Klein, et al:Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction:The Joint European Society of Cardiology/American College of Cardiology Committee. J Am Coll Cardiol 36:959-969, 2000
 
3) White H:Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction:the HERO-2 randomised trial. Lancet 358:1855-1863, 2001.
 
4) John K French, Harvey D White:Clinical implications of the new definition of myocardial infarction. Heart 90:99-106, 2004.
PubMed
5) 1998-1999年度合同研究班報告:循環器病の診断と治療に関するガイドライン. Jpn Circ J 64 Supplement IV:1081-1127.
 
P.77 掲載の参考文献
1) Forrester JS, Diamond GA, Swan HJC:Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol 39:137-145, 1977.
 
2) 磯部光章:症候の評価と治療の実際, 心不全患者. 内科学会雑誌92:764-769, 2004.
 
3) Braunwald E, et al:Valvular Heart Diseas. in Heart Disease (ed Braunwald E, Saunders, Co), pp1653-1655, Philadelphia, 2001.
 
4) 磯村正:虚血性僧帽弁閉鎖不全症に対する外科治療. 循環器科55:117-122, 2004.
 
5) Menicanti L, Donato M, Frigiola A, et al:Ischemic mitral regurgitation:Intraventricular papillary muscle imbrication without mitral ring during left ventricular restoration. J Thorac Cardiovasc Surg 123:1041-1050, 2002.
PubMed
P.82 掲載の参考文献
1) Shinbane JS, Wood MA, Jensen DN, et al:Tachycardia-induced cardiomyopathy:a review of animal models and clinical studies. J Am Coll Cardiol 29:709-715, 1997.
PubMed
2) Peters KG, Kienzle MG:Severe cardiomyopathy due to chronic rapidly conducted atrial fibriliation:complete recovery after restoration of sinus rhythm. Am J Med 85:242-244, 1988.
 
3) Gosselink AT, Blanksma PK, Crijns HT, et al:Left ventricular beat-to-beat performance in atril fibrillation:contribution of Frank-Straling after short rather than long RR intervals. J Am Coll Cardiol 26:1516-1521, 1995.
 
4) Koretsune Y, Marban E:Cell calcium in the pathophysiology of ventricular fibrillation and in the pathogenesis of postarrhythmic contractile dysfunction. Circulatin 80:369-379, 1989.
 
5) 山下武志:不整脈治療の目的と適応. 心房細動の治療. 日独医報 48 (special edition 1):31-47, 2003.
 
6) Haisaguerre M, Jais P, Shah DC, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. J Cardiovasc Electrophysiol 10:136-144, 1998.
 
P.86 掲載の参考文献
1) Ross J Jr, Braunwald E:Aortic stenosis. Circulation 38 (suppl V):V61-67, 1968.
 
2) Julias BK, Spillmann M:Angina pectoris in patients with aortic stenosis and normal coronary arteries:Mechanisms and pathophysiological concepts. Circulation 95:892-898, 1997.
 
3) Passik CS, Ackermann DM, Pluth JR, et al:Temporal changes in the cause of aortic stenosis:a surgical pathologic study of 646 cases. Mayo Clin Proc 62:119-123, 1987.
PubMed
4) Galan A, Zoghbi WA, Quinones MA:Determination of severity of valvuler aortic stenosis by Doppler echocardiography and relation of findings to clinical outcome and agreement with hemodynamic measurements determined at cardiac catheterization. Am J Cardiol 67:1007-1012, 1991.
 
5) Pellikka PA, Nishimura RA, Bailey KR, et al:The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 15:1012-1017, 1990.
PubMed
6) Shah PM, Graham BM:Management of aortic stenosis:is cardiac catheterization necessary? Am J Cardiol 67:1031-4032, 1991.
PubMed
7) Rajappan K, Rimoldi OE, et al:Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation 105:470-476, 2002.
PubMed
8) Kelly T, et al:Comparison of outcome of asymptmatic to symptomatic patients older than 20 years of age with valvular aortic stenosis. Am J Cardiol 61:123-130, 1988.
 
9) Croft LB, Goldman ME:Calcific aortic stenosis:new pathophysiologic insights and possible new medical therapy. Curr Cardiol Rep 5:101-104, 2003.
PubMed
10) Shavelle DM, Takasu J, et al:HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359:1125-1126, 2002.
PubMed
11) 弁膜疾患の非薬物治療に関するガイドライン. Circulation Journal 66 (Suppl IV), 2002.
 
P.90 掲載の参考文献
1) S Lalchandani, M Wingfield:Pregnancy in women With Malfan:s Syndrome. European Joumal of Obsterics & Gynecology and Reproductive Biology 110:125-130, 2003.
 
2) Cheistos Alexiou, FRCS, Stephen M Langley, et al:Aortic Root Replacement in Patients With Marfan's Syndrome:The Southampton Experience. Ann thorac Surg 72:1502-1508, 2001.
 
3) Fabio Quondamatteo, Dieter P Reinhardt, Noe L Charbonneau, et al:Fibrillin-land fibrillin-2 in human embryonic and earlyfetal development:Matrix Biology 21:637-646, 2002.
 
4) Lygia Pereira, Orna Levran, Francesco Ramirez, et al:A Molecular Approach to the Stratification of Cardiovascular Risk in Families with Marfan:s syndrome:N Engl J Med 331:148-153, 1994.
 
5) Barry J Maron, Chair;Lames H Moller, Cochair;Christine E Seidman, et al:Impact of Laboratry Molecular Diagnosis on Contemporary Diagnostic Criteria for Genetically Transmitted Cardiovascular Disease:Hypertrophic Cardiomyopathy, Long-QT Syndrome, and Marfan Syndrome:Circulation 98:1460-1471, 1998.
 
6) Richard B Devereux, Mary J Roman:Aortic Disease in Marfan:s Syndrome:N Engl J Med 340:1358-1359, 1999.
 
7) REED E PHYERITZ:Disorders of connective tissue:Heart Disease, Braunwarld, 2000-2003.
 
8) 丸山隆久, 戸塚信之, 赤羽邦夫ほか:妊娠中に大動脈解離を発症したMarfan症候群の2例. 呼と循41(1):8588, 1993.
 
P.102 掲載の参考文献
1) 佐藤光, 立石博信, 内田俊明, ほか:多枝spasmにより特異な左室造影像「ツボ型」を示したstunned myocardium. 臨床から見た心筋細胞障害. 虚血から心不全まで (児玉和久, ほか編). pp5664, 東京, 科学評論社, 1990.
 
2) Tsuchihashi K, Ueshima K, Uchida T, et al:Transient left ventricular apical ballooning without coronary artery stenosis:a novel heart syndrome mimicking acute myocardial infarction. J Am Coll Cardiol 38:11-18, 2001.
PubMed
3) 友池仁暢編:特集:たこつぼ心筋障害概念から治療まで-Heart View 8:2004.
 
4) 土橋和文, 長谷守:たこつぼ心筋障害の臨床像. Heart View 8:31-38, 2004.
 
5) 土手慶五, 佐藤光, 立石博信, ほか:冠動脈の蝋慢性攣縮により広範な心筋stunningを呈した5例. J Cardiol 21:203-214, 1991.
 
6) Kurisu S, Inoue I, Kawagoe T, et al:Myocardial perfusion and fatty acid metabolism in patients with Tako-Tsubo-like left ventricular dysfunction. J Am Coll Cardiol 41:743-748, 2003.
PubMed
7) 石田良雄, 福地樹, 宮崎俊一, ほか:たこつぼ心筋症における冠循環異常. Heart View 8:25-29, 2004.
 
8) Abe Y, Kondo M, Matsuoka R, et al:Assessment of clinical features in transient left ventricular apical ballooning. J Am Coll Cardiol 41:737-742, 2003.
PubMed
9) 河合祥雄:たこつぼ心筋障害 (たこつぼ心筋症) 診断の手引き (第2案) 作成過程. 心臓36:466468, 2004.
 
10) Matsuoka K, Okubo S, Fujii E, et al:Evaluation of the arrhythmogenecity of stress-induced "takotsubo cardiomyopathy" from the time course of the 12-lead surface electrocardiogram. Am J Cardiol 92:230-233, 2003.
PubMed
11) Owa M, Aizawa K, Urasawa N, et al:Emotional stress-induced:ampulla cardiomyopathy'-Discrepancy between the metabolic and sympathetic innervation imaging performed during the recovery course-. Jpn Circ J 65:349-352, 2001.
PubMed
12) 河合祥雄, 山田京志, 鈴木宏昌:"たこつぼ心筋障害T:の病理. Heart View 8:39-46, 2004.
 
13) Cebelin MS, Hirsch CS:Human stress cardiomyopathy:Myocardial lesions in victims of homicidal assaults without internal injuries. Human Pathol 11:123-132, 1980.
PubMed
14) 斎藤雅彦, E嶋健治:"たこつぼ心筋障害"急性期治療の考え方. Heart View 8:68-72, 2004.
 
15) Kyuma M, Tsuchihashi K, Shinshi Y, et al:Effect of intravenous Propranolol on left ventricular apical ballooning without coronary artery stenosis (Ampulla cardiomyopathy)-Three cases-. Circ J 66:1181-1184, 2002.
PubMed
16) 河合祥雄:たこつぼ型心筋障害, またはたこつぼ (Ampulla or Amphora) 心筋症. 本邦学会報告例の検討. 呼と循 48:1237-1248, 2000.
 
17) Kono T, Morita H, Kuroiwa T, et al:Left ventricular wall motion abnormalities in patients with subarachnoid hemorrhage:neurogenic stunned myocardium. J Am Coll Cardiol 24:636-640, 1994.
PubMed
18) Masuda T, Sato K, Izumi T:Subarachnoid hemorrhage and myocardial damage-from clinical study to animal experiment. 心臓 30:21-34, 1998.
 
19) Villareal RP, Achari A, Wilansky S, et al:Anteroapical stunning and left ventricular outiflow tract obstruction. Mayo Clin Proc 76:79-83, 2001.
PubMed
20) Ueyama T, Kasamatsu K, Hano T, et al:Emotional stress induced transient left ventricular hypocontraction in the rat via activation of cardiac adrenoceptors. A possible animal model of:Tako-Tsubo:cardiomyopathy. Circ J 66:712-713, 2002.
PubMed
P.107 掲載の参考文献
1) Pearson GD, Veille JC, Rahimtoola S, et al:Peripartum cardiomyopathy;National Heart, Lung, and Blood Institute and Othce of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283:1183-1188, 2000.
PubMed
2) Hull E, Hafkesbring E:Toxic postpartal heart disease. New orleans Med Sci J 89:550-557, 1937.
 
3) Meadows WR:Idiopathic myocardial failure in the last trimester of pregnancy and the puerperium. Circulation 15:903-914, 1957.
PubMed
4) Homans DC:Peripartum cardiomyopathy. N Engl J Med 312:1432-1437, 1985.
PubMed
5) 馬杉復三:妊娠に固有する特発性心筋不全症に就いて. 日病理会誌 28:254-259, 1938.
 
6) Whitehead SJ, Berg CJ, Chang J:Pregnancy-related mortality due to Cardiomyopathy:United States, 1991-1997. Obstet Gynecol 102:1326-1331, 2003.
PubMed
7) Burch GE, Giles TD, Tsui CY:Postpartal cardiomyopathy. Cardiovasc Clin 4:270-282, 1972.
PubMed
8) 猪尾力:産褥性心筋症. 特発性心筋症のすべて. 187-195, 1978.
 
9) 河合忠一:特発性心筋症診断の手引き. 厚生省特定疾患特発性心筋症調査研究班, 昭和60年研究報告集 13-15, 1986.
 
10) Demakis JG, Rahimtoola SH, Sutton GC, et al:Natural course of peripartum cardiomyopathy. Circulation 44:1053-1061, 1971.
PubMed
11) O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al:Peripartum cardiomyopathy:clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol 8:52-56, 1986.
PubMed
12) Felker GM, Jaeger CJ, Klodas E. et al:Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 140:785-791, 2000.
PubMed
13) Melvin KR, Richardson PJ, Olsen EG, et al:Peripartum cardiomyopathy due to myocarditis. N Engl J Med 307:731-734, 1982.
PubMed
14) Bozkurt B, Villaneuva FS, Holubkov R, et al:Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34:177-180, 1999.
PubMed
15) Felix SB, Staudt A, Landsberger M, et al:Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 39:646-652, 2002.
PubMed
16) Becker FF, Taube H:Myocarditis of obscure etiology associated with pregnancy. Nord Hyg Tidskr 266:62-67, 1962.
 
17) Yagoro A, Tada H, Hidaka Y, et al:Postpartum onset of acute heart failure possibly due to postpartum autoimmune myocarditis. A report of three cases. J Intern Med 245:199-203, 1999.
 
P.112 掲載の参考文献
1) Reardon W, Ross RDM, Sweeney MG, et al:Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet 340:1376-1379, 1992.
 
2) Ballinger SW, Shoffner JM, Hedaya EV, et al:Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. Nat Genet 1:11-15, 1992.
PubMed
3) Zeviani M, Gellera C, Antozzi C, et al:Maternally inherited myopathy and cardiomyopathy:association with mutation in mitochondrial DNA tRNA (Leu) (UUR). Lancet 338:143-147, 1991.
PubMed
4) Anan R, Nakagawa M, Miyata M, et al:Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 91:955-961, 1995.
 
5) Kadowaki T, Kadowaki H, Mori Y, et al:A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 330:962-968, 1994.
PubMed
6) 大林利博, 伊藤隆之:日本臨牀60:535-539, 2002.
 
7) Yoshida R, Ishida Y, Hozumi T, et al:Congestive heart failure in mitochondrial diabetes mellitus. Lancet 344:1375, 1994.
PubMed
8) Ueno H, Shiotani H:Cardiac abnormalities in diabetic patients with mutation in the mitochondrial tRNA (Leu (UUR)) gene. Jpn Circ J 63:877-880, 1999.
PubMed
9) Graham BH, Waymire KG, Cottrell B, et al:Amouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 16:226-234, 1997.
 
10) Li Y, Huang TT, Carlson EJ, et al:Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11:376-381, 1995.
PubMed
11) Wang J, Wilhelmsson H, Graff C, et al:Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet 21:133-137, 1999.
PubMed
12) Inoue K, Nakada K, Ogura A, et al:Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. Nat Genet 26:176-181, 2000.
PubMed
13) Yasukawa T, Suzuki T, Ueda T, et al:Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs (Leu) (UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. J Biol Chem 275:4251-4257, 2000.
PubMed
P.118 掲載の参考文献
1) Bernadine PH, Schlant RC, Gonzalez EB:The Heart and Connective Tissue Disease. Hurst's THE HEART Eight Edition, pp1921-1935, McGraw-Hill Inc, 1994.
 
2) Clements PJ:Systemic sclerosis and related syndromes. リウマチ入門第12版「日本語版」pp414-431, アメリカ関節炎財団日本リウマチ学会, 2001.
 
3) Solomon DH, Karlson EW, Rimm EB, et al:Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303-1307, 2003.
PubMed
P.123 掲載の参考文献
1) Gertz MA, Kyle RA, Thibodeau SN:Familial amyloidosis:Astudy of 52 North American-born patients examined during a 30-year period, Mayo Clin Proc 67:428, 1992.
 
2) Simons M, Isner JM:Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. Am J Cardiol 69:425, 1992.
PubMed
3) Tanaka M, Hongo M, Kinoshita O, et al:Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 29:168, 1997.
PubMed
4) Hongo M, Urushibata K, Kai Ryuichi, et al:Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 144:122, 2002.
PubMed
5) Rahman JE, Helou EF, Gelzer-Bell R, et al:Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43:410, 2004.
PubMed
6) Falk RH, Skinner M:The systemic amyloidosis:an overview. Adv Intern Med 45:107, 2000.
PubMed
7) Spyrou N, Foale R:Restrictive cardiomyopathies. Curr Opin Cardiol 9:344, 1994.
PubMed
8) Pollak A, Falk RH:Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 104:618, 1993.
PubMed
9) Kushwaha SS, Fallon JT, Fuster V:Restrictive cardiomyopathy. N Engl J Med 336:267, 1997.
PubMed
10) Skinner M, Anderson J, simms R. et al:Treatment of 100 patients with primary amyloidosis:arandomized trial of melphalan, prednispne, and colchicine versus colchicine only. Am J Med 100:290, 1996.
 
11) Kyle RA, Gertz MA, Greipp PR, et al:Atrial of three regimens for primary amyloidosis:colchicine alone, meiphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med 336:1202, 1997.
 
12) Sanchorawala V, Wright D, Seldin D, et al:An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplantation 28:637, 2001.
PubMed
13) Sanchorawala V, Wright DG, Seldin DC, et al:Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British J Haematology 117:886, 2002.
 
14) Alloni A, Pellegrini C, Ragni T, et al:Heart transplantation in patients with amyloidosis:single-center experience. Transplantation Proceedings 36:643, 2004.
PubMed
P.129 掲載の参考文献
1) Take M, et al:The Japanese survey of eosinophilic heart disease. Cardiomyopathy Update 3 (ed by Olsen EGJ, Sekiguchi M), Restrictive Cardiomyptayhy and Arrhythmias, p75, Univ Tokyo Press, Tokyo, 1990.
 
2) Fauci AS, et al:The Idiopathic hypereosinophilic syndrome, Annals of Intemal Medicine 97:78-92, 1982.
 
3) Chusid MJ, et al:The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine 54:1-27, 1975.
PubMed
4) Peter F, et al:The idiopathic hypereosinophilic syndrome. Blood 83:2759-2779, 1994.
 
5) Paradanani A, et al:Imatinib theray for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101:3391-3397, 2003.
 
6) Cools J, et al:Atyrosone kinase created by fusion of PDGFRA and FIPILI Genes as a Theraputic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. N Engl J med 348:1201-1214, 2003.
 
P.134 掲載の参考文献
1) 松森昭:心筋炎;内科学第8版 (杉本恒明, 小俣政男, 水野美邦総編集), pp692-695, 朝倉書店, 2003.
 
2) Matsumori A:Introductory chapter. in Cardiomyopathies and heart failure. Biomolecular, Infectious and Immune Mechanisms (Matsumori A, ed), pp1-15, Boston, Kluwer Academic Publishers, 2003.
 
3) Matsumori A, Furukawa Y, Hasegawa K, et al:Epidemilogic in Japan-Results from nationwide surveys. Circ J 66:323-336, 2002.
 
4) Matsumori A, Matoba Y, Sasayama S:Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92:2519-2525, 1995.
PubMed
5) Matsumori A, Yutani C, Ikeda Y, et al:Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 80:1137-1142, 2000.
PubMed
6) 松森昭:C型肝炎ウイルスと心筋症. Heart View 8:97-101, 2004.
 
7) Matsumori A:Hepatitis C virus infection and cardiomyopathies. Circ Res 96:pp144-147, 2005.
 
8) Matsumori A, Ohashi N, Ito H, et al:Genes of the major histocompability complex class II influence the phenotype of cardiomyopathies associated with hepatitis C virus infection. in Cardiomyopathies and heart failure (Matsumori A, ed), pp515-521, Boston, Kluwer Academic Publisherg., 2003.
 
9) Okada I, Matsumori A, Matoba Y, et al:Combination treatment with ribavirin and interferon for experimental coxsackievirus B3 replication. J Lab Clin Med 120:569-573, 1992.
 
10) Sato Y. Takatsu Y, Yamada T, et al:Treatment with interferon of dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponnin T. Jpn Circ J 64:321-324, 2000.
PubMed
11) 島田俊夫ほか:C型肝炎ウイルスによる潜在する心筋障害とそれに及ぼすインターフェロン効果. 厚生省特定疾患特発性心筋症調査研究班. 平成10年度報告書. pp82-91, 1995.
 
P.141 掲載の参考文献
1) 小出直:アルコール性心筋症. 内科56:1072-1076, 1985.
 
2) 政二文明ほか:アルコール性心筋障害. 臨床科学28:1217-1221, 1992.
 
3) Evans W:The electrocardiogram of alcoholic cardiomyopathy. Br Heart J 21:445-456, 1959.
PubMed
4) Burch GE, et al:Cardiac insufficiency in chronic alcoholism. Am J Cardiol 6:864-874, 1960.
PubMed
5) 谷村晃:アルコール性心筋症 (Alcoholic Cardiomyopathy) の病理. 病理と臨床1:549-554, 1983.
 
6) 上北和実ほか:断酒により心機能及び心筋組織所見が改善したアルコール性心筋症の1例. 呼吸と循環 2:201-205, 1997.
 
7) 真先敏弘ほか:骨格筋症候群その他の神経筋疾患を含めて. アルコール性心筋症. 日本臨林別冊骨格筋症候群下巻:398400, 2001.
 
8) 竹端均ほか:特発性心筋症と特定心筋疾患. 特定心筋疾患 (-1次性心筋疾患) 特発性心筋症との関連を中心に. アルコール性心疾患. 日本臨床 58:151-156, 2000.
 
9) 斎藤靖浩ほか:超音波検査の技術と臨床. 循環器心血1管疾患各論. 心筋症 (二次性心筋症). 臨床検査 45:1373-1376, 2001.
 
10) 小出直:内科臨床における心筋障害. アルコール性心筋症, 変貌しつつあるその概念. 診断と治療 79:2463-2468, 1991.
 
11) 和泉徹ほか:心筋疾患. アルコール性心筋疾患. 日本臨牀別IHf循環器症候群III:15-21, 1996.
 
12) Nicolas JM, et al:The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med 136:192-200, 2002.
PubMed
13) 河合忠一:心筋症の概念. 病理と臨床1:528-531, 1983.
 
14) Ettinger PO, et al:Arrhythmias and the"Holiday Heart":alcohol-associated cardiac rhythm disorders. Am Heart J 95:555 562, 1978.
 
15) Braunwald E:Heart Disease:A textbook of cardiovascular medicine, 5th ed (ed by Braunwald E), pp1412-1414, Philadelphia, W B Saunders Company, 1997.
 
P.145 掲載の参考文献
1) 島薗順次郎:脚気. 日内会誌7:237, 1919.
 
2) Wolf PL. et al:Shoshin beriberi. N Engl J Med 30:1302, 1960.
 
3) Kawai C, et al:Reappearance of beriberi heart disease in Japan. Am J Med 69:383-386, 1980.
PubMed
4) Akbarian M. et al:Hemodynamic studies in beriberi heart disease. Am J Med 41:197-212, 1966.
PubMed
5) Okura H, et al:High-output heart failure as a cause of pulmonary hypertension. Intern Med 6:363-365, 1994.
PubMed
6) 大倉宏之ほか:心エコー・ドプラ法により収縮及び拡張動態を経過観察しえた衝心脚気の1例. JMed Ultrasonics 24:1845-1849, 1997.
 
P.150 掲載の参考文献
1) Mein I, Ojamaa K:Thyroid hormone and the cardiovascular system. N Engl J Med 344:501-509, 2001.
 
2) 心房細動治療 (薬物) ガイドライン. Jpn Circ J 65 (Suppl V):931-998, 2001.
 
3) Krahn AD, Klein GJ, Kerr CR, et al:How useful is thyroid function testing in patients with recent-onset atrial fibrillation? Arch Intern Med 156:2221-2224, 1996.
PubMed
4) Forfar JC, Miller HC, Toft AD:Occult thyrotoxicosis:a reversible cause of idiopathic atrial fibrillation. Am J Cardiol 44:9-12, 1979.
PubMed
5) Hellman R, Kelly KL, Mason WD:Propranolol for thyroid storm. N Engl J Med 297:671-672, 1977.
PubMed
6) Roti E, Montermin M, Roti S, et al:The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med 148:1919-1921, 1988.
 
7) Nakazawa HK, Sakurai K, Hamada N, et al:Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 72:903-906, 1982.
PubMed
8) Shimizu T, Koide S, Noh JY, et al:Hyperthyroidism and the management of atrial fibrillation. Thyroid 12:489-493, 2002.
PubMed
9) Sawin CT, Geller A, Wolf PA, et al:Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older patients. N Engl J Med 331:1249-1252, 1994.
 
10) Sawin CT:Subclinical Hyperthyroidism and Atrial Fibrillation. Thyroid 12:501-503, 2002.
PubMed
P.159 掲載の参考文献
1) Vasan RS, Larson MG, Benjamin EJ, et al:Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction:prevalence and mortality in a population-based cohort, J Am Coll Cardiol 33:1948-1955, 1999.
 
2) Tsutsui H, Tsuchihashi M, Takeshita A:Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88:530-533, 2001.
PubMed
3) Hogg K, et al:Heart failure with preserved left ventricular systolic function. Epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43:317-327, 2004.
PubMed
4) Gandhi SK, Powers JC, Nomeir AM, et al:The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344:17-22, 2001.
PubMed
5) Jessup M, Brozena S:Heart Failure. New Engl J Med 348:2007-2018, 2003.
PubMed
6) Zile MR, Brutsaert DL:New concepts in diastolic dysfunction and diastolic heart failure. Part I:diagnosis, prognosis, and measurements of diastolic function. Circulation 105:1387-1393, 2002.
PubMed
7) Vasan RS, et al:Defining diastolic heart failure:a call for standardized diagnostic criteria. Circulation 101:2118-2121, 2000.
 
8) Yusuf S, Pfeffer MA, Swedberg K et al:Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial, Lancet 362:777-781, 2003.
PubMed
9) Senni M, Tribouilloy CM, Rodeheffer RJ, et al:Congestive heart failure in the community:astudy of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98:2282-2289, 1998.
 
P.165 掲載の参考文献
1) Pawan K Singal, Natasha Iliskovic:Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998.
 
2) 相原康, 倉林正彦:薬剤性心筋症. 「心筋症」 (松森昭編), pp215-221, メジカルビュー社, 2000.
 
3) Kakuya Kitagawa, et al:Differences in fatty acid metabolic disorder between ischemic myocardium and doxorubicin-induced myocardial damage:Assessment using BMIPP dynamic SPECT with analysis by the Rutland method. J Nucl Med 43:1286-1294, 2002.
 
4) Braunwald E:Cardiac effects of radiation therapy and chemotherapy. In "Heart Disease;A Textbook of Cardiovascular Medicine (6th ed)" (Braunwald E ed), pp2233-2236, WB Saunders Company, 2001.
 
5) Schwartz RG, et al:Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 82:1109-1118, 1987.
PubMed
6) Billingham ME, et al:Antracycline cardiomyopathy monitored bymorphologic changes. Cancer Treat Rep 62:865-872, 1978.
 
7) Bristow MR, et al:Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50:32-41, 1982.
PubMed
8) 森本紳:郎ほか:特定心筋症. 「心筋炎・心筋症」 (和泉徹編), pp187-191, 大阪,永井書店, 2000.
 
9) 岡田義信ほか:Anthracycline系薬剤による心毒性の心エコー図による検討癌と化学療法 24:585-589, 1997.
 
P.171 掲載の参考文献
1) Dec GW, Fuster V:Idiopathic dilated cardiomyopathy. N Eng J Med 331:1564-1575, 1994.
 
2) Mestroni L, Rocco C, Gregori D, et al:Familial dilated cardiomyopathy:evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 34:181-190, 1999.
 
3) Sugrue DD, Rodeheffer RJ, Codd MB, et al:The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med 117:117-123, 1992.
PubMed
4) Packer M, Bristow MR, Cohn JN, et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Eng J Med 334:1349-1355, 1996.
 
5) Felker GM, Thompson RE, Hare JM, et al:Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Eng J Med 342:1077-1084, 2000.
 
6) Richardson P, McKenna W, Bristow M, et al:Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93:841-842, 1996.
PubMed
7) Antiplatelet Trialis:Collaboration:Collaborative overview of randomized trials of antiplatelet therapy-1:Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit Med J 308:81-106, 1994.
 
8) The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 336:25-33, 1997.
 
9) Pitt D:ACE inhibitor co-therapy in patients with heart failure:rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 16 (Suppl N):107-110, 1995.
 
10) The CONSENSUS Trial Study Group:Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 316:1429-1435, 1987.
 
11) The SOLVD Investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991.
PubMed
12) Otsuji Y, Kumanohoso T. Yoshifuku S, et al:Isolated annular dilation does not usually cause important functional mitral regurgitation:comparison between patients with lone atrial fibrillation and those with idiopathic or ischemic cardiomyopathy. J Am Coll Cardiol 39:1651-1656, 2002.
PubMed
P.181 掲載の参考文献
1) 日本循環器学会心臓移植委員会ホームページ:http://plaza.umin.ac.jp/~hearttp/
 
2) Therrien J, Marx GR, Gatzoulis MA:Late problems in tetralogy of Fallot-recognition, management, and prevention. Cardiology Clinics 20:395404, 2002.
 
3) Sejung S, Young T L:Outcome of adults with repaired tetralogy of Fallot. J Korean Med Sci 15:37-43, 2000.
 
P.186 掲載の参考文献
1) Bradley TD, Floras JS:Sleep apnea and heart failure. Part I:Obstructive sleep apnea. Circulation 107:1671-1678, 2003.
PubMed
2) Sin DD, Fitzgerald F. Parker JD, et al:Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 160:1101-1106, 1999.
PubMed
3) Javaheri S, Parker TJ, Liming JD, et al:Sleep apnea in 81 ambulatory male patients with stable heart failure:types and their prevalences, consequences, and presentations. Circulation 97:2154-2159, 1998.
PubMed
4) 麻野井英次:自律神経機能と循環障害. 日本臨床 58:1599-1603, 2000.
 
5) Lanfranchi PA, Braghiroli A, Bosimini E, et al:Prognostic value of noctumal Cheyne-Stokes respiration in chronic heart failure. Circulation 99:1435-1440, 1999.
 
6) Naughton MT, Benard DC, Liu PP, et al:Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 152:473-479, 1995.
PubMed
7) Sin DD, Logan AG, Fitzgerald FS, et al:Effect of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 102:61-66, 2000.
PubMed
8) Bradley TD, Floras JS:Sleep apnea and heart failure. Part II:Central sleep apnea. Circulation 107:1671-1678, 2003.
 
9) Hanly PJ, Millar TW, Steljes DG, et al:The effect of oxygen on respiration and sleep in patients with congestive heart failure. Ann Int Med 111:777-782, 1989.
PubMed
10) Andreas S, Clemens C, Sandholzer H, et al:Improvement of exercise capacity with treatment of Cheyne-Stokes respiration in patients with congestive heart failure. J Am Coll Cardiol 27:14861490, 1996.
 
11) Javaheri J:A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 341:949-954, 1999.
 
P.191 掲載の参考文献
1) 慢性心不全治療ガイドライン. Jpn Circ J 64:1023-1079, 2000.
 
2) Burch GE, et al:Ischemic cardiomyopathy. Am Heart J 179 (suppl):291-292, 1970.
 
3) Richardson P, et al:Report of the 1995 WHO/ISFC task force on definition and classification of cd:rdiomyopathies. Circulation 93:841-842, 1996.
 
4) Lavee J, et al:Prediction of mortality in patients awaiting cardiac transplantation:increased risk of sudden death in ischemic to idiopathic dilated cardiomyopathy.
PubMed
5) Packer M, et al:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U S Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996.
 
6) Gottlieb SS, et al:Effect of beta blockade on mortality among high-risk and low risk patients after myocardial infarction. N Engl J Med 339:489-497, 1998.
PubMed
7) Packer M, et al:The effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001.
PubMed
8) 心筋梗塞二次予防に関するガイドライン. ダイジェスト板. Jpn Circ J 64 (suppl):1081-1127, 2000.
 
9) 急性重症心不全治療ガイドライン. Jpn Circ J 64 (suppl):1129-1165, 2000.
 
10) Wilson K, et al:Effect of smoking cessation on mortality after myocardial infarction:meta-analysis of cohort study. Arch Intern Med 160:939-944, 2000.
PubMed
11) Scandinavian Simbastatin Survival Study Group:Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simbastatin Survival Study (4S). Lancet 344:1383-1389, 1994.
 
12) Hori M, et al:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004.
PubMed
P.197 掲載の参考文献
1) Gottypaty VK, Krelis SP, Lu F, et al:The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure. J Am Coll Cardiol 33 (suppl):145A, 1999.
 
2) Leclerbeq C, Faris O, Turin R, et al:Systolic improvement and mechanical resynchronization does not require electrical synchrony in dilated failing heart with left bundle branch block. Circulation 106:1760-1766, 2002.
 
3) Yu CM, Chau E, Sanderson JE, et al:Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing. Circulation 105:438-445, 2002.
PubMed
4) Hamdan MH, Zagrodzyky JD, Joglar JA, et al:Biventricular pacing decreases sympathetic nerve activity compared with right ventricular pacing in patients with depressed ejection fraction. Circulation 102:1027-1034, 2000.
 
5) Cazeau S, Ritter P, Lazarus A, et al:Multisite pacing for end-stage heart failure;early experience. PACE 19 (11 Pt2):17481757, 1996.
 
6) Abraham WT, Fisher WG, Smith AL, et al:MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002.
 
7) Bristow MR, Saxon LA, Boehmer J, et al:Cardiac Resynchronization Therapy with or without Implantable Defibrillator in Advanced Chronic Heart Failure. N Engl J Med 350:2140-2150, 2004.
 
8) ACC/AHA/NASPE Committee to Update the 1988 Pacemaker Guideline. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker and Antiarrhtthmia Devices:Summary Article A Report of the American College of Cardiology/American Heart Association Task Force on Pracrice Guideline. Circulation 106:2145-2161, 2002.
 
9) Ansalone G, Glannanioni P, Ricci R, et al:Doppler myocardial imaging to evaluate the effectiveness of pacing sites in receiving biventricular pacing. J Am Coll Cardiol 39:489-499, 2002.
PubMed
10) Linde C, Lecleroq C, Rex S, et al:Long-term bemefits of biventricular pacing in congestive heart failure:results from the multisite stimulation in carduimyopathy (MUSTIC) study. J Am Coll Cardiol 40:111-118, 2002.
 
P.202 掲載の参考文献
1) Iwai K, Sekiguchi M., Hosoda Y,, et al:Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 11:26-31, 1994.
 
2) 江石義信:サルコイドーシスの成因論. 成因にかかわる候補起因体研究の最新動向. 日本臨床60:1688-1696, 2002.
 
3) 平賀洋明, 岩井和郎, 廣江道昭, ほか:心臓サルコイドーシス診断の手引き 1992-作成の経過について. 厚生省特定疾患「びまん性肺疾患」調査研究班平成4年度報告集:23-24, 1993.
 
4) Yoshida Y, Morimot S, Hiramitsu S, et al:Incidence of cardiac sarcoidosis in Japanese patients with high-degreeatrioventricular block. Am Heart J 134:382-386, 1997.
 
5) 加藤靖周, 森本紳, 郎,平光伸也, ほか:診断の手引きを満たさないものの, 心臓サルコイドーシスが強く疑われた2症例. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 19:91-96, 1999.
 
6) Iwai K, Tachibana T, Takemura T, et al:Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 casesin Japan. Acta Pathol Jpn 43:372-376, 1993.
 
7) Valantine H, McKenna WJ, Nihoyannopoulos P, et al:Sarcoidosis:Apattern of clinical and morphological presentation. Br Heart J 57:256-263, 1987.
 
8) Shimada T, Shimada K, Sakane T, et al:Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy bygadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 110:591-592, 2001.
 
9) Uemura A, Morimoto S, Hiramitsu S, et al:Positive rates of various clinical parameters in cardiac sarcoidosis. Circ J 68 (Suppl I):582, 2004.
 
P.209 掲載の参考文献
1) Vitali E, Colombo T, Fratto P, et al:Surgical therapy in advanced heart failure. Am J Cardiol 91:88F-94F, 2003.
PubMed
2) Kyo S, Tanabe H, Asano H, et al:Clinical effects of ventricular assist system on the patients with end-stage cardiac failure-advantages of left ventricular drainage for the recovery of cardiac dysfunction. Jpn Thorac Cardiovasc Surg 48:440-446, 2000.
 
3) Wieselthaler GM, Schima H, worschak M, et al:First experiences with outpatient care of patients With implanted axial fiow pumps. Artif Organs 25:331-335, 2001.
 
4) Vitali E, Lanfranconi M, Ribera E, et al:Successful experience in bridging patients to heart transplantation with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg 75:1200-1204, 2003.
PubMed
5) Burke DJ, Burke E, Parsaie F, et al:The Heartmate II:design and development of a fully sealed axial flow left ventricular assist system. Artif Organs 25:380-385, 2001.
PubMed
6) Frazier OH, Myers TJ, Gregoric ID, et al:Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation 105:2855-2860, 2002.
PubMed
7) Westaby S, Jarvik R, Freeland A, et al:Postauricular percutaneous power delivery for permanent mechanical circulatory support. J Thorac Cardiovasc Surg 123:977-983, 2002.
PubMed
8) Frazier OH:Implantation of the Jarvik 2000 left ventricular assist device without the use of cardiopulmonary bypass. Ann Thorac Surg 75:1028-1030, 2003.
PubMed
9) Saito S, Westaby S, Piggott D, et al:Reliable long-term non-pulsatile circulatory support without anticoagulation. Eur J Cardiothorac Surg 19:678-683, 2001.
 
10) Yamazaki K, Kihara S, Akimoto T, et al:EVAHEART:an implantable centrifugal blood pump for long-term circulatory support. Jpn J Thorac Cardiovasc Surg 50:461-465, 2002.
PubMed
11) el-Banayosy A, Korfer R:Long-term implantable left ventricular assist devices:out-of-hospital program. Cardiol Clin 21:57-65, 2003.
PubMed
12) No authors listed:AbioCor totally implantable artificial heart. How will it impact hospitals? Health Devices 31:332-341, 2002.
 
13) 中谷武嗣, 笹子佳門, 駒村和雄, ほか:左補助人工心臓より離脱し得た拡張型心筋症の2例. 第15回日本心臓移植研究会. (大阪, 2, 15), 抄録36頁.
 
14) Rose EA, Gelijns AC, Moskowitz AJ, et al:Long-term use of a left ventricular assist device for end-stage heart failure. N Engl JMed 345:1435-1443, 2001.
 
P.213 掲載の参考文献
1) Trulock EP, Edwards LB, Taylor DO, et al:The Registry of the International Society for Heart and Lung Transplantation:Twentieth Official adult lung and heart-lung transplant reportム2003. J Heart Lung Transplant 22:625-635, 2003.
 
2) Marconi C, Marzorati M:Exercise after heart transplantation. Eur J Appl Physiol 90:250-259, 2003.
PubMed
3) Cowen SW, Coscia LC, Philips LZ, et al:Pregnancy outcomes in female heart and heart-lung transplant recipients. Trasplant Proc 34:1855-1856, 2002.
 

書評

最近チェックした商品履歴

Loading...